Literature DB >> 24158781

CXCR4 pathway associated with family history of melanoma.

Wen-Qing Li1, Jiali Han, Hans R Widlund, Mick Correll, Yaoyu E Wang, John Quackenbush, Martin C Mihm, Alvaro Laga Canales, Shaowei Wu, Todd Golub, Yujin Hoshida, David J Hunter, George Murphy, Thomas S Kupper, Abrar A Qureshi.   

Abstract

PURPOSE: Genetic predisposition plays a major role in the etiology of melanoma, but known genetic markers only account for a limited fraction of family-history-associated melanoma cases. Expression microarrays have offered the opportunity to identify further genomic profiles correlated with family history of melanoma. We aimed to distinguish mRNA expression signatures between melanoma cases with and without a family history of melanoma.
METHODS: Based on the Nurses' Health Study, family history was defined as having one or more first-degree family members diagnosed with melanoma. Melanoma diagnosis was confirmed by reviewing pathology reports, and tumor blocks were collected by mail from across the USA. Genomic interrogation was accomplished through evaluating expression profiling of formalin-fixed paraffin-embedded tissues from 78 primary cutaneous invasive melanoma cases, on either a 6K or whole-genome (24K) Illumina gene chip. Gene set enrichment analysis was performed for each batch to determine the differentially enriched pathways and key contributing genes.
RESULTS: The CXC chemokine receptor 4 (CXCR4) pathway was consistently up-regulated within cases of familial melanoma in both platforms. Leading edge analysis showed four genes from the CXCR4 pathway, including MAPK1, PLCG1, CRK, and PTK2, were among the core members that contributed to the enrichment of this pathway. There was no association between the enrichment of CXCR4 pathway and NRAS, BRAF mutation, or Breslow thickness of the primary melanoma cases.
CONCLUSIONS: We found that the CXCR4 pathway might constitute a novel susceptibility pathway associated with family history of melanoma in first-degree relatives.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24158781      PMCID: PMC4100594          DOI: 10.1007/s10552-013-0315-9

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  38 in total

1.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

2.  A versatile assay for high-throughput gene expression profiling on universal array matrices.

Authors:  Jian-Bing Fan; Joanne M Yeakley; Marina Bibikova; Eugene Chudin; Eliza Wickham; Jing Chen; Dennis Doucet; Philippe Rigault; Baohong Zhang; Richard Shen; Celeste McBride; Hai-Ri Li; Xiang-Dong Fu; Arnold Oliphant; David L Barker; Mark S Chee
Journal:  Genome Res       Date:  2004-05       Impact factor: 9.043

Review 3.  Cancer and the chemokine network.

Authors:  Fran Balkwill
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

4.  FAK integrates growth-factor and integrin signals to promote cell migration.

Authors:  D J Sieg; C R Hauck; D Ilic; C K Klingbeil; E Schaefer; C H Damsky; D D Schlaepfer
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

Review 5.  Dysplastic nevi and melanoma.

Authors:  Alisa M Goldstein; Margaret A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

6.  Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors.

Authors:  D Anderson; C A Koch; L Grey; C Ellis; M F Moran; T Pawson
Journal:  Science       Date:  1990-11-16       Impact factor: 47.728

7.  Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.

Authors:  Stefania Scala; Alessandro Ottaiano; Paolo Antonio Ascierto; Manuela Cavalli; Ester Simeone; Paola Giuliano; Maria Napolitano; Renato Franco; Gerardo Botti; Giuseppe Castello
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 8.  The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.

Authors:  Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

9.  Familial melanoma, pancreatic cancer and germline CDKN2A mutations.

Authors:  Alisa M Goldstein
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

10.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

View more
  3 in total

Review 1.  Epidemiological Assessments of Skin Outcomes in the Nurses' Health Studies.

Authors:  Wen-Qing Li; Eunyoung Cho; Martin A Weinstock; Hasan Mashfiq; Abrar A Qureshi
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

2.  Host Characteristics and Risk of Incident Melanoma by Breslow Thickness.

Authors:  Wen-Qing Li; Eunyoung Cho; Shaowei Wu; Suyun Li; Natalie H Matthews; Abrar A Qureshi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-19       Impact factor: 4.254

3.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.